Venetoclax (ABT-199)

For research use only. Not for use in humans.

Catalog No.S8048 Synonyms: GDC-0199

321 publications

Venetoclax (ABT-199) Chemical Structure

Molecular Weight(MW): 868.44

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 680 In stock
USD 270 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Venetoclax (ABT-199) has been cited by 321 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.
Features Re-engineered version of ABT-263 (Navitoclax).
Bcl-2 [1]
(Cell-free assay)
<0.01 nM(Ki)
In vitro

ABT-199 shows less sensitivity to Bcl-xL, Mcl-1 and Bcl-w with Ki of 48 nM, > 444 nM and 245 nM, respectively. ABT-199 potently inhibits FL5.12-Bcl-2 cells, RS4;11 cells with EC50 of 4 nM and 8 nM, while shows low activity against FL5.12-Bcl-xL cells with EC50 of 261 nM. ABT-199 induces a rapid apoptosis in RS4;11 cells with cytochrome c release, caspase activation, the externalization of phosphatidylserine and the accumulation of sub-G0/G1 DNA. Quantitative immunoblotting reveals that sensitivity to ABT-199 correlated strongly with the expression of Bcl-2, including NHL, DLBCL, MCL, AML and ALL cell lines. ABT-199 also induces apoptosis in CLL with an average EC50 of 3.0 nM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CS-THL1 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PXOlIxKG6P MWW3NkBp NX\ZdIU4TE2VTx?= NVfjcIkxUW6qaXLpeJMh[2WubDDndo94fGhiYYPz[ZN{\WRiYomgZ4VtdCC4aXHibYxqfHl? NGfNUlUzPTlzNk[5PC=>
CS-THL1 MVPBdI9xfG:2aXOgRZN{[Xl? NVzze3NzOjVibl2= MXfEUXNQ NUXyTmg{UW6mdXPld{BieG:ydH;zbZM> MYiyOVkyPjZ7OB?=
DoGKiT MWDBdI9xfG:2aXOgRZN{[Xl? NYHaSpp3PTBibl2= MkDQSG1UVw>? NYXqN2xqUW6mdXPld{BieG:ydH;zbZM> NYflWlZqOjV7MU[2PVg>
RS4-11 NIj2dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjyd4M4OiCq NV7rb5hxUUN3ME2wMlA1ODJizszN NIDyT|IzPTZ2OUe2PC=>
NALM-6 NHHSdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETveZQ4OiCq M3:zbmlEPTB-MzFOwG0> Ml[5NlU3PDl5Nki=
SU-DHL-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfzNE45KM7:TR?= MYfJcohq[mm2czDj[YxtKGe{b4f0bEBie3Onc4Pl[EBjgSClZXzsJJZq[WKrbHn0fS=> M4rnO|I2PTlyOECz
OCI-Ly19 NWjhW49mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxJO69VQ>? Ml:zTY5pcWKrdIOgZ4VtdCCpcn;3eIgh[XO|ZYPz[YQh[nliY3XscEB3cWGkaXzpeJk> M1SwV|I2PTlyOECz
SU-DHL-6 NUDiV5VGTnWwY4Tpc44hSXO|YYm= MUOwMlc2KM7:TR?= M{TLcFE5KGh? MlnnTY5kemWjc3XzJJBzdy2|dYL2bZZidCCycn;0[YlvKE2FTD2xJIV5eHKnc4Ppc44> MYOyOVU6ODhyMx?=
ALL-SIL NWCxU|hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jlbVExKM7:TR?= NVHMbYQ{PDhiaB?= M3vS[mROW09? M2HnZ2lEPTB;MD6xPFA{KM7:TR?= MofpNlU{ODF5MES=
KOPTK1 M3vYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnINVAh|ryP M{LPVVQ5KGh? MlTkSG1UVw>? M3G2U2lEPTB;MD62OFMzKM7:TR?= Mm[1NlU{ODF5MES=
PEER MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXyNVAh|ryP NVqybGhvPDhiaB?= MWfEUXNQ MoexTWM2OD12Lk[0NFMh|ryP MkPiNlU{ODF5MES=
CX-1 NXLwNo0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37z[VExOCEQvF2= MUG3NkBp MmPLTWM2OD14Lkeg{txO MVKyOVIxQDh6Mh?=
LS147T M3rFSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWxNFAh|ryP MkXoO|IhcA>? NUTCWWFbUUN3ME2yPU42KM7:TR?= MmXDNlUzODh6OEK=
HL-60 NGrhbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm0PEBp NV;hOYRvUUN3MEyxJO69VQ>? MXKyOFM1PjFzNh?=
MOLM-13 MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEniS|g1QCCq MW\JR|UxRDFizszN MmjDNlQ{PDZzMU[=
OCI-AML2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[0PEBp NXjPUHprUUN3MEyxJO69VQ>? MkWwNlQ{PDZzMU[=
Kasumi-1 NIDyeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfieFdvPDhiaB?= M{jr[WlEPTB:MTFOwG0> NXrUdXg{OjR|NE[xNVY>
KG-1 NHr5e|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7kOFghcA>? MYnJR|UxRDFizszN M3;rS|I1OzR4MUG2
THP-1 M{\PfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzP[VlmPDhiaB?= NEnCbmxKSzVyPEGg{txO NYPPcVBXOjR|NE[xNVY>
MOLM-14 NIDUe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4TlQ5KGh? M4jGSWlEPTB:MTFOwG0> M2H3SVI1OzR4MUG2
MOLM-13 NVTyc25GSXCxcITveIlkKEG|c3H5 M4PvVFUxKG6P M4LWO|I1KGh? MVnBdI9xfG:|aYOgbY5lfWO2aX;u MnLiNlQ{PDZzMU[=
MOLT4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxNEDPxE1? NWm2fll4PDhiaB?= M2XEd2ROW09? MoLPTWM2OD12LkG1OEDPxE1? NHLrS|kzPDN2Mkm0PC=>
SKW-3/KE-37 M4D3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\ofVNFOTBizszN NWPmN3ZMPDhiaB?= M3n5SWROW09? NIq3To1KSzVyPUCuO|EzKM7:TR?= M4qxUlI1OzR{OUS4
SUPT-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD0NVAh|ryP NILjUY41QCCq MlHCSG1UVw>? NXfBWW1lUUN3ME20MlQ4OyEQvF2= M{OwOVI1OzR{OUS4
CCRF-CEM MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxNEDPxE1? NUO0T2J3PDhiaB?= MnzwSG1UVw>? M{DYZ2lEPTB;MT6zOlAh|ryP M1\kN|I1OzR{OUS4
LOUCY NEL3bmlCeG:ydH;0bYMhSXO|YYm= M1P2[lIh|ryP NXO5cJFnPDhiaB?= MoH3SG1UVw>? NWT4WoZpSXCxcITvd4l{KGmwZIXjeIlwdg>? M3rXdlI1OzR{OUS4

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
Mcl-1 / Bcl-xl / Bcl-2 / Bak / NOXA / Bim; 

PubMed: 30663221     

A549 cells were treated with Ibr-7, ABT-199 or a combination for 2 or 4 h. Total RNA was extracted from A549 cells to undergo RT-qPCR assay.

PARP / Cleaved PARP / Caspase 3 / Cleaved caspase3 / p-S6(Ser236/236); 

PubMed: 30663221     

A549 cells were treated with Ibr-7, ABT-199 or a combination for 24 h before western blotting assay. 

Growth inhibition assay
Cell death; 

PubMed: 28714472     

The indicated cell lines, treated with 2 μM doxorubicin±1 or 2 μM ABT-199, were quantified by annexin-V staining at 24 h for H2171 and H446 or at 48 h for H196 and SW1271 (mean±s.d., n=3). 

Cell viability; 

PubMed: 29876007     

TNBC cells were cultured with the indicated doses of ABT-199 (μM) for 48 h. 

28714472 29876007
Bcl-2 / Mcl-1; 

PubMed: 28767232     

HEK293T cells cotransfected with the plasmids. Upon transfection, DMSO carrier control, 0.5 μM ABT-199, 10 μM A1210477, or a combination of both 0.5 μM ABT-199 and 10 μM A1210447 were added to the cells. After 30 h, the cells were analyzed for GFP and RFP expression by fluorescence microscopy.

In vivo ABT-199 (100 mg/kg) causes a maximal tumor growth inhibition of 95% and tumor growth delay of 152% in RS4;11 xenografts. ABT-199 also inhibits xenograft growth (DoHH2, Granta-519) as a single agent or in combination with SDX-105 and other agents. [1]


Kinase Assay:[1]
- Collapse

Binding affinity assays:

Binding affinities (Ki or IC50) of ABT-199 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-199 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:[1]
- Collapse
  • Cell lines: NHL, DLBCL, MCL, AML and ALL cell lines
  • Concentrations: ~1 μM
  • Incubation Time: 48 hours
  • Method: RS4;11 cells are seeded at 5 × 104 per well in 96-well plates and treated with ABT-199 diluted in half-log steps starting at 1 μM-0.05 nM. Leukemia and lymphoma cell lines are seeded at 1.5-2 × 104 cells per well in the appropriate medium and incubated with ABT-199 for 48 h. Effects on proliferation are determined using Cell TiterGlo reagent. EC50 values are determined by nonlinear regression analysis of the concentration-response data.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female C.B-17 SCID mice (DoHH2 and Granta-519 xenografts) and female C.B-17 SCID-beige mice (RS4;11 and Toledo xenografts)
  • Formulation: 60% phosal 50 propylene glycol (PG), 30% polyethylene glycol (PEG) 400 and 10% ethanol
  • Dosages: ~100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (115.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 868.44


CAS No. 1257044-40-8
Storage powder
in solvent
Synonyms GDC-0199
Smiles CC1(C)CCC(=C(C1)C2=CC=C(Cl)C=C2)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)N[S](=O)(=O)C5=CC=C(NCC6CCOCC6)C(=C5)[N+]([O-])=O)OC7=CN=C8[NH]C=CC8=C7

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04073147 Not yet recruiting Drug: Venetoclax|Drug: Obinutuzumab Primary CNS Lymphoma Klinikum Stuttgart|University Hospital Freiburg November 2019 Phase 1
NCT04070768 Not yet recruiting Drug: Gemtuzumab Ozogamicin|Drug: Venetoclax Acute Myeloid Leukemia Big Ten Cancer Research Consortium|Pfizer|AbbVie October 2019 Phase 1
NCT03943342 Not yet recruiting Drug: Ibrutinib|Drug: Venetoclax Chronic Lymphocytic Leukemia|Loss of Chromosome 17p Kerry Rogers|National Cancer Institute (NCI)|Janssen Research & Development LLC|Ohio State University Comprehensive Cancer Center September 1 2019 Phase 2
NCT03900884 Not yet recruiting Drug: Venetoclax|Drug: Palbociclib|Drug: Letrozole Breast Neoplasm Female Peter MacCallum Cancer Centre Australia September 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you please offer some advice on the half-life of the drug ?

  • Answer:

    According to the reference (, the half-life of ABT-199 in dogs is 12.9 hr.

  • Question 2:

    how to prepare the working solution for mice including how to dissolve the powder?

  • Answer:

    We recommend the following vehicle for ABT 199, 30% PEG400/0.5% Tween80/5% Propylene glycol (64.5% water, V/V), at a concentration up to 20mg/ml. Its a homogeneous suspension and can be used for oral gavage.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Venetoclax (ABT-199) | Venetoclax (ABT-199) supplier | purchase Venetoclax (ABT-199) | Venetoclax (ABT-199) cost | Venetoclax (ABT-199) manufacturer | order Venetoclax (ABT-199) | Venetoclax (ABT-199) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID